Zydus Lifesciences Limited — Updates, 18-01-2025: Press Release

Zydus Lifesciences has received approval from the USFDA to initiate a Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor, targeting patients with Amyotrophic Lateral Sclerosis (ALS). This randomized, double-blind, placebo-controlled trial will evaluate Usnoflast's efficacy, safety, and pharmacokinetics over a 36-week treatment period, followed by a 16-week open-label extension. The study aims to enroll 210 ALS patients and measure the change in ALSFRS-R total score as its primary endpoint. The Chairman of Zydus expressed excitement about this development, emphasizing the company’s commitment to advancing neuroscience and developing innovative treatments. With ALS impacting approximately 32,000 people in the USA alone, this trial could pave the way for significant healthcare advancements and offers a positive outlook for the company's pipeline in neurological therapies.